What does Life Sciences at Goldman Sachs Alternatives invest in?
Life Sciences at Goldman Sachs Alternatives invests most often at Series B (100% of the rounds on record).
Last cheque observed Aug 2026; 1 cheques on record.
Deploying nowGrowth equity
Follow Life Sciences at Goldman Sachs Alternatives and see its new cheques in your feed.Start following
1 cheques in the last 12 months
Mostly Series B: 100% of its rounds
Led 1 rounds
Every round we can evidence, newest first1 appearances
1 round
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
Life Sciences at Goldman Sachs Alternatives invests most often at Series B (100% of the rounds on record).
1 investments on record, 1 of them in the last 12 months, and it led 1. The most recent was in Aug 2026.
Its most recent investments on record: Vaderis Therapeutics (Series B, Aug 2026).
The median round it joins is $152M.
Yes: it is actively investing, with 1 investments in the last 12 months.
Life Sciences at Goldman Sachs Alternatives is a growth equity firm.
From 3 articles and filings naming it in a round, public registers and its own website, checked and rebuilt every night.
Find the investors who back rounds like yours, and keep every conversation on one fundraising board.
Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it